Press Release  
6 May 2013

**Annual General Meeting in Enzymatica AB (publ)**

**At Enzymaticas Annual General Meeting today 6 May 2013, Christian Westin Jansson was elected new Chairman of the Board of Directors and Anders Jungbeck was elected new Board member. The meeting further resolved, *inter alia*, to implement an incentive program to employees and external Board members who work actively for the Company, and to authorize the Board to issue new shares.**

The AGM voted in favour of adopting the income statements and balance sheets for the group and the parent company, and resolved that the funds available at the general meeting should be carried forward and that thus no dividend should be paid for the financial year 2012.

The AGM discharged the Board members and the CEO from liability, reelected the ordinary Board members Fredrik Lindberg and Jörgen Rexö and elected Christian Westin Jansson as new Chairman of the Board and Anders Jungbeck as new Board member. No fees will be paid to the Board members.

Furthermore, the AGM authorized the Board to resolve on the issue of no more than 2,000,000 new shares, with or without a deviation from the shareholders’ preferential right, for the purpose of enabling the raise of capital to finance the Company’s continuous expansion and for the purpose enabling company acquisitions or acquisition of all or parts of business entities.

Last the AGM resolved, in accordance with the Board’s proposal, to implement a long term incentive program in the form of an option program comprising employees and external active Board members of Enzymatica. The new Option Program 2013/2017 shall include a maximum of 850,000 options.

**For more information, please contact:**

Michael Edelborg Christensen, CEO

Telephone: +46 (0)76-814 41 66

[michael.christensen@enzymatica.se](mailto:michael.christensen@enzymatica.se)

About Enzymatica AB (publ)  
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical devices based on patented enzyme technology. Enzymatica utilizes a cold-adapted trypsin derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. Enzymatica has two registered medical device products, PeriZyme chewing gum CE, against oral cavity diseases and ColdZyme Mouth Spray CE against common cold, the latter recently launched in pharmacies throughout the country.